| Drug Name |
Saxagliptin hydrochloride |
| Drug ID |
BADD_D01993 |
| Description |
Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. |
| Indications and Usage |
Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy. |
| Marketing Status |
Prescription |
| ATC Code |
A10BH03 |
| DrugBank ID |
DB06335
|
| KEGG ID |
D10262
|
| MeSH ID |
C502994
|
| PubChem ID |
49800073
|
| TTD Drug ID |
D0Y6QC
|
| NDC Product Code |
62756-209; 50370-0039; 55111-960 |
| Synonyms |
saxagliptin | 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate | Onglyza | BMS 477118 | BMS477118 | BMS-477118 |
